Day One Biopharmaceuticals (DAWN) Competitors $6.84 +0.08 (+1.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$6.84 0.00 (-0.07%) As of 04/17/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. SWTX, PTGX, CPRX, MRUS, ALVO, APLS, SRRK, CRNX, IMVT, and ACADShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. SpringWorks Therapeutics Protagonist Therapeutics Catalyst Pharmaceuticals Merus Alvotech Apellis Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Immunovant ACADIA Pharmaceuticals SpringWorks Therapeutics (NASDAQ:SWTX) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Do analysts rate SWTX or DAWN? SpringWorks Therapeutics currently has a consensus price target of $73.20, indicating a potential upside of 93.20%. Day One Biopharmaceuticals has a consensus price target of $32.29, indicating a potential upside of 372.01%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SpringWorks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community believe in SWTX or DAWN? SpringWorks Therapeutics received 52 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 71.62% of users gave SpringWorks Therapeutics an outperform vote while only 70.13% of users gave Day One Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformSpringWorks TherapeuticsOutperform Votes10671.62% Underperform Votes4228.38% Day One BiopharmaceuticalsOutperform Votes5470.13% Underperform Votes2329.87% Is SWTX or DAWN more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -134.73%. Day One Biopharmaceuticals' return on equity of -22.40% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SpringWorks Therapeutics-134.73% -46.74% -41.12% Day One Biopharmaceuticals N/A -22.40%-19.79% Does the media refer more to SWTX or DAWN? In the previous week, SpringWorks Therapeutics had 2 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 9 mentions for SpringWorks Therapeutics and 7 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 1.26 beat SpringWorks Therapeutics' score of 0.96 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SpringWorks Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Day One Biopharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of SWTX or DAWN? 87.9% of Day One Biopharmaceuticals shares are owned by institutional investors. 7.6% of SpringWorks Therapeutics shares are owned by insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, SWTX or DAWN? Day One Biopharmaceuticals has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpringWorks Therapeutics$191.59M14.82-$325.10M-$3.48-10.89Day One Biopharmaceuticals$131.16M5.29-$188.92M-$1.08-6.33 Which has more volatility and risk, SWTX or DAWN? SpringWorks Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.24, meaning that its share price is 224% less volatile than the S&P 500. SummaryDay One Biopharmaceuticals beats SpringWorks Therapeutics on 13 of the 19 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$693.27M$6.44B$5.29B$7.35BDividend YieldN/A3.25%5.12%4.31%P/E Ratio-6.646.8821.7117.77Price / Sales5.29231.36379.3997.68Price / CashN/A65.6738.2234.64Price / Book1.725.916.443.98Net Income-$188.92M$142.72M$3.21B$247.44M7 Day Performance1.18%7.98%5.24%4.44%1 Month Performance-21.11%-13.91%-9.49%-7.73%1 Year Performance-53.94%-9.98%11.01%1.28% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.7334 of 5 stars$6.84+1.2%$32.29+372.0%-53.9%$693.27M$131.16M-6.6460Positive NewsSWTXSpringWorks Therapeutics2.2353 of 5 stars$36.99-5.4%$73.20+97.9%-14.1%$2.77B$191.59M-10.63230Options VolumeNews CoverageHigh Trading VolumePTGXProtagonist Therapeutics3.792 of 5 stars$43.21-2.8%$62.56+44.8%+81.0%$2.65B$434.43M16.24120News CoveragePositive NewsCPRXCatalyst Pharmaceuticals4.6098 of 5 stars$21.81-5.5%$32.29+48.0%+40.8%$2.65B$491.73M18.4880Positive NewsGap DownHigh Trading VolumeMRUSMerus2.9738 of 5 stars$37.39-1.9%$85.31+128.2%+4.9%$2.58B$36.13M-9.4737ALVOAlvotech1.5474 of 5 stars$8.32-2.1%$18.00+116.3%-35.2%$2.51B$489.68M-4.501,026Gap DownAPLSApellis Pharmaceuticals4.1381 of 5 stars$19.80-0.9%$45.59+130.2%-62.1%$2.49B$781.37M-9.75770Analyst RevisionNews CoverageGap DownSRRKScholar Rock3.8831 of 5 stars$26.04-3.2%$42.67+63.9%+124.1%$2.47B$33.19M-11.08140News CoveragePositive NewsGap DownCRNXCrinetics Pharmaceuticals3.6073 of 5 stars$26.38-1.9%$73.00+176.7%-30.9%$2.45B$1.04M-7.07210IMVTImmunovant2.1907 of 5 stars$14.39-1.3%$41.00+184.9%-46.7%$2.44BN/A-5.49120Insider TradeShort Interest ↑ACADACADIA Pharmaceuticals4.0238 of 5 stars$14.61-5.0%$23.93+63.8%-14.3%$2.44B$957.80M18.73510Analyst Revision Related Companies and Tools Related Companies SpringWorks Therapeutics Competitors Protagonist Therapeutics Competitors Catalyst Pharmaceuticals Competitors Merus Competitors Alvotech Competitors Apellis Pharmaceuticals Competitors Scholar Rock Competitors Crinetics Pharmaceuticals Competitors Immunovant Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
